{"id":556514,"date":"2021-08-06T14:42:01","date_gmt":"2021-08-06T14:42:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=556514"},"modified":"2021-08-06T14:42:01","modified_gmt":"2021-08-06T14:42:01","slug":"hyperopia-market-insights-epidemiology-and-market-forecast2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/hyperopia-market-insights-epidemiology-and-market-forecast2030_556514.html","title":{"rendered":"Hyperopia Market Insights, Epidemiology, And Market Forecast-2030"},"content":{"rendered":"
\n
\"Hyperopia<\/a><\/div>\n
\n
DelveInsight Business Research LLP <\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s \u2018Hyperopia Market Insights, Epidemiology, and Market Forecast\u20142030\u2019 report delivers an in-depth understanding of the Hyperopia , historical and forecasted epidemiology as well as the Hyperopia market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.<\/p>\n<\/div>\n

Hyperopia Market<\/strong><\/p>\n

DelveInsight’s ‘Hyperopia Market<\/a>’ report delivers an in-depth understanding of the Hyperopia , historical and forecasted epidemiology as well as the Hyperopia market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.<\/p>\n

The Hyperopia market report <\/a>provides current treatment practices, emerging drugs, Hyperopia market share of the individual therapies, current and forecasted Hyperopia market size from 2018 to 2030 segmented by seven major markets. The Report also covers current Hyperopia treatment practice\/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.<\/p>\n

Hyperopia Market Outlook<\/strong><\/p>\n

Key Findings<\/p>\n

The Hyperopia market size <\/a>in the 7MM is expected to change during the study period 2018–2030, at a CAGR of 1.0%. According to the estimates, the highest market size of Hyperopia is accessed in the United States followed by Japan, and Germany, in 2020.<\/p>\n

The United States Market Outlook<\/p>\n

In United States, the total market size of Hyperopia therapies is expected to increase at a CAGR of 1.2% during the study period (2018–2030).<\/p>\n

EU-5 Countries: Market Outlook<\/p>\n

In EU-5, the total market size of Hyperopia therapies is expected to increase at a CAGR of 0.8% during the study period (2018–2030).<\/p>\n

Japan Market Outlook<\/p>\n

The total market size of Hyperopia therapies in Japan is estimated to rise at a CAGR of 0.8%, during the study period (2018–2030).<\/p>\n

Hyperopia Pipeline Development Activities<\/strong><\/p>\n

The drugs which are in pipeline include:<\/p>\n

1. NVK-029: Nevakar<\/p>\n

2. NVK-039: Nevakar<\/p>\n

Request for sample pages @ Hyperopia Market Size <\/a><\/p>\n

Table of contents<\/p>\n

1.Key Insights<\/p>\n

2.Report Introduction<\/p>\n

3.Hyperopia Market Overview at a Glance<\/p>\n

3.1. Market Share (%) Distribution of Hyperopia in 2018<\/p>\n

3.2. Market Share (%) Distribution of Hyperopia in 2030<\/p>\n

4.Executive Summary of Hyperopia<\/p>\n

5.Epidemiology and Market Forecast Flow<\/p>\n

6.Disease Background and Overview<\/p>\n

6.1.Introduction<\/p>\n

6.2 Signs and Symptoms<\/p>\n

6.3. Classification<\/p>\n

6.4. Causes of Hyperopia<\/p>\n

6.5. Clinical types of hyperopia<\/p>\n

6.6.Complications<\/p>\n

6.7.Pathophysiology<\/p>\n

6.8.Diagnosis<\/p>\n

6.8.1.   Testing<\/p>\n

7.Current Treatment<\/p>\n

7.1. Prescription lenses<\/p>\n

7.1.1.   Eyeglasses<\/p>\n

7.1.2.   Contact lenses<\/p>\n

7.2.Refractive surgery<\/p>\n

7.2.1.   Laser-assisted in situ keratomileusis (LASIK)<\/p>\n

7.2.2.   Laser-assisted subepithelial keratectomy (LASEK)<\/p>\n

7.2.3.   Photorefractive keratectomy (PRK)<\/p>\n

7.2.4.   Conductive Keratoplasty<\/p>\n

7.2.5.   Phakic Intraocular Lens<\/p>\n

7.2.6.   Refractive Lens Exchange<\/p>\n

7.3. Lifestyle and other home remedies<\/p>\n

8.Epidemiology and Patient Population<\/p>\n

8.1. Key Findings<\/p>\n

8.2. Assumptions and Rationale<\/p>\n

8.3. Epidemiology Scenario: 7MM<\/p>\n

8.3.1.   Total Prevalent Cases of Hyperopia in the 7MM<\/p>\n

8.3.2.   Total Diagnosed Prevalent cases of Hyperopia in the 7MM<\/p>\n

8.3.3.   Gender-specific Diagnosed Prevalent Cases of Hyperopia in the 7MM<\/p>\n

8.3.4.   Age-specific Diagnosed Prevalent Cases of Hyperopia in the 7MM<\/p>\n

8.3.5.   Severity-Specific Diagnosed Prevalent Cases of Hyperopia in the 7MM<\/p>\n

8.3.6.   Treated cases of Hyperopia in the 7MM<\/p>\n

8.4. The United States<\/p>\n

8.4.1.   Total Prevalent Cases of Hyperopia in the United States<\/p>\n

8.4.2.   Total Diagnosed Prevalent cases of Hyperopia in the United States<\/p>\n

8.4.3.   Gender-specific Diagnosed Prevalent Cases of Hyperopia in the United States<\/p>\n

8.4.4.   Age-specific Diagnosed Prevalent Cases of Hyperopia in the United States<\/p>\n

8.4.5.   Severity-Specific Diagnosed Prevalent Cases of Hyperopia in the United States<\/p>\n

8.4.6.   Treated cases of Hyperopia in the United States<\/p>\n

8.5.EU-5 Epidemiology<\/p>\n

8.6.Germany<\/p>\n

8.6.1.   Total Prevalent Cases of Hyperopia in Germany<\/p>\n

8.6.2.   Total Diagnosed Prevalent cases of Hyperopia in Germany<\/p>\n

8.6.3.   Gender-specific Diagnosed Prevalent Cases of Hyperopia in Germany<\/p>\n

8.6.4.   Age-specific Diagnosed Prevalent Cases of Hyperopia in Germany<\/p>\n

8.6.5.   Severity-Specific Diagnosed Prevalent Cases of Hyperopia in Germany<\/p>\n

8.6.6.   Treated cases of Hyperopia in Germany<\/p>\n

8.7.France<\/p>\n

8.7.1.   Total Prevalent Cases of Hyperopia in France<\/p>\n

8.7.2.   Total Diagnosed Prevalent cases of Hyperopia in France<\/p>\n

8.7.3.   Gender-specific Diagnosed Prevalent Cases of Hyperopia in France<\/p>\n

8.7.4.   Age-specific Diagnosed Prevalent Cases of Hyperopia in France<\/p>\n

8.7.5.   Severity-Specific Diagnosed Prevalent Cases of Hyperopia in France<\/p>\n

8.7.6.   Treated cases of Hyperopia in France<\/p>\n

8.8. Italy<\/p>\n

8.8.1.   Total Prevalent Cases of Hyperopia in Italy<\/p>\n

8.8.2.   Total Diagnosed Prevalent cases of Hyperopia in Italy<\/p>\n

8.8.3.   Gender-specific Diagnosed Prevalent Cases of Hyperopia in Italy<\/p>\n

8.8.4.   Age-specific Diagnosed Prevalent Cases of Hyperopia in Italy<\/p>\n

8.8.5.   Severity-Specific Diagnosed Prevalent Cases of Hyperopia in Italy<\/p>\n

8.8.6.   Treated cases of Hyperopia in Italy<\/p>\n

8.9. Spain<\/p>\n

8.9.1.   Total Prevalent Cases of Hyperopia in Spain<\/p>\n

8.9.2.   Total Diagnosed Prevalent cases of Hyperopia in Spain<\/p>\n

8.9.3.   Gender-specific Diagnosed Prevalent Cases of Hyperopia in Spain<\/p>\n

8.9.4.   Age-specific Diagnosed Prevalent Cases of Hyperopia in Spain<\/p>\n

8.9.5.   Severity-Specific Diagnosed Prevalent Cases of Hyperopia in Spain<\/p>\n

8.9.6.   Treated cases of Hyperopia in Spain<\/p>\n

8.10.The United Kingdom<\/p>\n

8.10.1. Total Prevalent Cases of Hyperopia in the United Kingdom<\/p>\n

8.10.2. Total Diagnosed Prevalent cases of Hyperopia in the United Kingdom<\/p>\n

8.10.3. Gender-specific Diagnosed Prevalent Cases of Hyperopia in the United Kingdom<\/p>\n

8.10.4. Age-specific Diagnosed Prevalent Cases of Hyperopia in the United Kingdom<\/p>\n

8.10.5. Severity-Specific Diagnosed Prevalent Cases of Hyperopia in the United Kingdom<\/p>\n

8.10.6. Treated cases of Hyperopia in the United Kingdom<\/p>\n

8.11. Japan Epidemiology<\/p>\n

8.11.1. Total Prevalent Cases of Hyperopia in Japan<\/p>\n

8.11.2. Total Diagnosed Prevalent cases of Hyperopia in Japan<\/p>\n

8.11.3. Gender-specific Diagnosed Prevalent Cases of Hyperopia in Japan<\/p>\n

8.11.4. Age-specific Diagnosed Prevalent Cases of Hyperopia in Japan<\/p>\n

8.11.5. Severity-Specific Diagnosed Prevalent Cases of Hyperopia in Japan<\/p>\n

8.11.6. Treated cases of Hyperopia in Japan<\/p>\n

9. Patient Journey<\/p>\n

10. Hyperopia: Seven Major Market Analysis<\/p>\n

10.1. Key Findings<\/p>\n

10.2. Market Outlook<\/p>\n

10.3. 7MM Market Size<\/p>\n

10.3.1. Total Market Size of Hyperopia in the 7MM<\/p>\n

10.3.2. Market Size of Hyperopia by Treatment Options in the 7MM<\/p>\n

10.4. The United States Market Size<\/p>\n

10.4.1. Total Market Size of Hyperopia in the United States<\/p>\n

10.4.2. Market Size of Hyperopia by Treatment Options in the United States<\/p>\n

10.5.  EU-5 Market Size<\/p>\n

10.6.  Germany<\/p>\n

10.6.1. Total Market size of Hyperopia in Germany<\/p>\n

10.6.2. Market Size of Hyperopia by Treatment Options in Germany<\/p>\n

10.7.  France<\/p>\n

10.7.1. Total Market size of Hyperopia in France<\/p>\n

10.7.2. Market Size of Hyperopia by Treatment Options in France<\/p>\n

10.8.  Italy<\/p>\n

10.8.1. Total Market size of Hyperopia in Italy<\/p>\n

10.8.2. Market Size of Hyperopia by Treatment Options in Italy<\/p>\n

10.9.  Spain<\/p>\n

10.9.1. Total Market size of Hyperopia in Spain<\/p>\n

10.9.2. Market Size of Hyperopia by Treatment Options in Spain<\/p>\n

10.10. The United Kingdom<\/p>\n

10.10.1. Total Market size of Hyperopia in the United Kingdom<\/p>\n

10.10.2. Market Size of Hyperopia by Treatment Options in the United Kingdom<\/p>\n

10.11. Japan<\/p>\n

10.11.1. Total Market size of Hyperopia in Japan<\/p>\n

10.11.2. Market Size of Hyperopia by Treatment Options in Japan<\/p>\n

11. KOL Views<\/p>\n

12. Market Access and Reimbursement<\/p>\n

13. Market Drivers<\/p>\n

14. Market Barriers<\/p>\n

15. SWOT Analysis<\/p>\n

16.Unmet Needs<\/p>\n

17.Appendix<\/p>\n

17.1. Bibliography<\/p>\n

17.2. Report Methodology<\/p>\n

18.DelveInsight Capabilities<\/p>\n

19. Disclaimer<\/p>\n

20. About DelveInsight<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight<\/a>
Contact Person:<\/strong> Priya Maurya
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 09650213330
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Albany
State:<\/strong> New York
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight Business Research LLP DelveInsight\u2019s \u2018Hyperopia Market Insights, Epidemiology, and Market Forecast\u20142030\u2019 report delivers an in-depth understanding of the Hyperopia , historical and forecasted epidemiology as well as the Hyperopia market trends in the United States, EU5 (Germany, France, Italy, … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,423,420,403,404],"tags":[],"class_list":["post-556514","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/556514","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=556514"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/556514\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=556514"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=556514"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=556514"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}